Novo’s ‘triple G’ shows competitive weight loss in partner’s Phase II

One day after Novo Nordisk’s valuation took a hit when CagriSema failed to match the efficacy of Lilly’s Zepbound, the Danish pharma got a consolation prize: promising Phase II data from a next-generation obesity program.

United Biotechnology, a subsidiary of United Laboratories International Holdings Ltd. (HKEX:3933), which granted Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) ex-China rights to UBT251 last year, announced results from a Phase II trial in China. The triple agonist of GLP-1R, GIPR and GCGR produced up to 19.7% weight loss at the highest dose, versus 2% for placebo, after 24 weeks — for a placebo-adjusted loss of 17.7%...